EP Patent

EP3893880A1 — Methods for treating heterotopic ossification

Assigned to Clementia Pharmaceuticals Inc · Expires 2021-10-20 · 5y expired

What this patent protects

The invention describes dosing regimens for treating subjects with fibrodysplasia ossificans progressiva characterized by a quiescent period and a non-quiescent period, wherein a therapeutically effective amount of palovarotene is administered to the subjects during the non- quie…

USPTO Abstract

The invention describes dosing regimens for treating subjects with fibrodysplasia ossificans progressiva characterized by a quiescent period and a non-quiescent period, wherein a therapeutically effective amount of palovarotene is administered to the subjects during the non- quiescent period, little or no palovarotene is administered to the subjects during the quiescent period, and imatinib is administered to the subjects during the quiescent period and optionally during the non-quiescent period. The dosing regimens can reduce heterotopic ossification, reduce the number of flare- ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.

Drugs covered by this patent

Patent Metadata

Patent number
EP3893880A1
Jurisdiction
EP
Classification
—
Expires
2021-10-20
Drug substance claim
No
Drug product claim
No
Assignee
Clementia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.